|Immunovative 2008 news release|
Immunovative announces today that pre-clinical data demonstrating the ability of AlloStim™ to act as a powerful adjuvant for therapeutic cancer vaccines was published on-line today in the medical journal Leukemia Research. You can view a copy of this paper by following this link.
Immunovative announced today that pre-clinical research demonstrating the efficacy of AlloStim™ has been published in the peer-reviewed medical journal Leukemia Research. The article can be viewed by following this link.
A new newsletter has been distributed by email to all shareholders. Any shareholder that has not received the newsletter please contact firstname.lastname@example.org and send a note to update your email address in our database.
Immunovative Therapies announces that a Notice of Allowance was issued 6-3-08, on the US Patient Application entitled: Allogeneic Cell Therapy: Mirror Effect. This patent provides broad coverage of the novel mechanism of action and composition of matter of the AlloStim™ product.
Immunovative Therapies announces today that the US Patent Office has issued a Notice of Allowance for application entitled “CELL THERAPY FORMULATION METHOD AND COMPOSITION”. This patent provides broad protection for the AlloStim™ formulation and cell composition.
Immunovative announced today it has posted a new animation on the website to describe the new AlloVax™ product being prepared for human clinical testing. AlloVax™ is designed to treat patients with newly diagnosed hematological malignancies. AlloVax™ is a personalized cancer vaccine that combines technology developed by Dr. Emmanual Katsanis and his colleagues at the University of Arizona for purification of “chaperone proteins” and our AlloStim™ product. Immunovative has purchased an exclusive license to the chaperone protein patent held by the University of Arizona. Immunovative is currently converting the chaperone protein technology to comply with Good Manufacturing Practices (GMP) required for initiation of human clinical trials. Click here to see the animation.
Immunovative announces today that it has been awarded NIS 1,083,661 (approximately $270,915) one year grant from the Israel Office of the Chief Scientist (OCS) of the Ministry of Industry and Trade. The funds are applied retroactive from Aug 1, 2007 to July 31, 2008. These funds are designated to support our development efforts for producing clinical grade AlloStim for use in our Phase I/II clinical trial at Hadassah Medical Center in Jerusalem which awaiting final approval from the Ministry of Health to begin accruing patients. Information about the OCS grant program can be viewed by clicking here.